罗格列酮治疗原发性高血压合并2型糖尿病临床评价 |
| |
引用本文: | 廖伟东,李桂平,陈丽芬.罗格列酮治疗原发性高血压合并2型糖尿病临床评价[J].中国现代医生,2010,48(5):13-14,16. |
| |
作者姓名: | 廖伟东 李桂平 陈丽芬 |
| |
作者单位: | 1. 广东省惠州市第三人民医院,药剂科,广东惠州,516002 2. 广东省惠州市第三人民医院,心血管肾内科,广东惠州,516002 |
| |
摘 要: | 目的探讨罗格列酮治疗原发性高血压合并2型糖尿病的降压效果。方法将200例病人随机分为罗格列酮联合治疗(治疗组)100例和常规治疗(对照组)100例,观察两组的临床疗效及治疗前和治疗后2~12周血压变化。结果治疗组总有效92例(92.0%),显著高于对照组72例(72.0%)(u=2.99,P0.05);治疗组治疗后第12周收缩压(16.08±1.68)kPa]、舒张压(10.09±1.61)kPa]明显低于治疗前(20.73±0.70)kPa、(13.71±0.84)kPa(]t=3.01,t=4.05,P均0.01);对照组治疗后第12周收缩压(17.74±2.86)kPa]、舒张压(10.92±1.61)kPa]明显低于治疗前(20.73±0.70)kPa、(13.67±0.81)kPa](t=3.05,t=3.15,P0.01);治疗组2~10周收缩压、舒张压较对照组比较下降明显(t=1.98~2.64,P均0.05);两组收缩压和舒张压第8周后血压处于较平稳状态。结论罗格列酮对原发性高血压有良好的降压作用,且安全性较好。
|
关 键 词: | 高血压 糖尿病 罗格列酮 降压 |
Treatment of Essential Hypertension with Type 2 Diabetes with Rosiglitazone:Clinical Evaluation |
| |
Authors: | LIAO Weidong LI Guiping CHEN Lifen |
| |
Affiliation: | LIAO Weidong1 LI Guiping2 CHEN Lifen1 1.Department of Pharmacology,2.Department of Medicine with Cardiovascular , Nephrology,Huizhou City Third People\'s Hospital,Huizhou 516002,China |
| |
Abstract: | Objective To investigate the curative effect of rosiglitazone on essential hypertension with type 2 diabetes.Methods We divided 200 cases of essential hypertension with type 2 diabetes randomly into Rosiglitazone combination therapy(treatment group,100 cases)and conventional therapy(control group 100 cases).The curative effect and blood pressure changes before treatment and at 2 to 12 weeks after treatment were observed.Results The total effective rate was 92.0%(92 cases)in the treatment group,significantly... |
| |
Keywords: | Hypertension Diabetes Rosiglitazone Hypotension |
本文献已被 CNKI 维普 万方数据 等数据库收录! |
|